Condition (MeSH)
Trophoblastic Neoplasms
ClinicalTrials.gov lists 75 trials for Trophoblastic Neoplasms or a narrower condition beneath it. Gynecologic Oncology Group has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
6 of the 75 trials are tagged with Trophoblastic Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Trophoblastic Neoplasms trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 7 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 4 |
| 2018 | 2 |
| 2017 | 2 |
Showing 10 of 28 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 10 trials still running at the 2026-10-09 snapshot; registered median of 35 months across 35 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Trophoblastic Neoplasms trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 24 |
| Phase 2/3 | 4 |
| Phase 3 | 10 |
| Phase 4 | 1 |
| Not applicable | 8 |
| Observational | 21 |
How many Trophoblastic Neoplasms trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 13 |
| Active, not recruiting | 5 |
| Completed | 32 |
| Terminated | 5 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Trophoblastic Neoplasms trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gynecologic Oncology Group | 6 |
| Children's Oncology Group | 3 |
| Tracon Pharmaceuticals Inc. | 2 |
| AstraZeneca | 1 |
Which drugs are being tested for Trophoblastic Neoplasms? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Dactinomycin | 7 |
| NIVOLUMAB | 2 |
| G-CSF | 2 |
| TORIPALIMAB | 2 |
| Cytoxan | 2 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HD- Methotrexate (MTX) | 7 |
| or carboplatin | 4 |
| Etoposid | 4 |
| Ifosfamid | 3 |
| AG chemotherapy | 2 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Trophoblastic Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile Neutropenia | 6 | 1 |
| Infection | 2 | 1 |
| Vomiting | 2 | 1 |
| Appendicitis | 1 | 1 |
| Diarrhea | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Trophoblastic Neoplasms? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Japan Society of Gynecologic Oncology guidelines 2013 for the treatment of uterine body neoplasms. | International journal of clinical oncology | 2016 | Yes |
| Management and outcome of healthy women with a persistently elevated beta-hCG. | Gynecologic oncology | 2007 | Yes |
| The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). | British journal of obstetrics and gynaecology | 1989 | Yes |
| The effects of some anti-oestrogens on the deciduoma reaction and delayed implantation in the mouse. | Journal of reproduction and fertility | 1968 | Yes |
| Trophoblastic disease. | Minnesota medicine | 1967 | Yes |
Showing 5 of 6 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.